STOCK TITAN

Biocept to Release Second Quarter 2020 Financial Results and Host Investor Conference Call on August 12, 2020

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and six months ended June 30, 2020 after the market closes on Wednesday, August 12, 2020.  The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers.  Those interested in listening to a webcast of the live conference call may do so by visiting https://www.webcaster4.com/Webcast/Page/1271/35627.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10145918.  A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Contact:              
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-release-second-quarter-2020-financial-results-and-host-investor-conference-call-on-august-12-2020-301104404.html

SOURCE Biocept, Inc.

Biocept, Inc.

NASDAQ:BIOC

BIOC Rankings

BIOC Latest News

BIOC Stock Data

1.14M
2.62M
9.21%
1.98%
0.57%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Diego

About BIOC

biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar